David Mcerlane Sells 1,994 Shares of Catalent, Inc. (NYSE:CTLT) Stock

Catalent, Inc. (NYSE:CTLT) insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Catalent Stock Down 0.1 %

Catalent stock traded down $0.08 during trading hours on Friday, reaching $60.21. The stock had a trading volume of 440,001 shares, compared to its average volume of 2,100,392. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $61.20. The company has a market cap of $10.90 billion, a price-to-earnings ratio of -9.88, a PEG ratio of 2.32 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. The business’s 50 day moving average price is $59.64 and its 200-day moving average price is $57.31.

Catalent (NYSE:CTLT) last posted its earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Sell-side analysts anticipate that Catalent, Inc. will post 0.85 EPS for the current year.

Wall Street Analyst Weigh In

CTLT has been the subject of several recent analyst reports. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, July 11th. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. StockNews.com assumed coverage on shares of Catalent in a research note on Thursday. They issued a “sell” rating for the company. Finally, Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday. One investment analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $59.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Catalent by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock worth $1,151,872,000 after acquiring an additional 218,682 shares during the last quarter. Capital World Investors lifted its holdings in shares of Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after purchasing an additional 1,098,474 shares during the period. Cadian Capital Management LP boosted its position in Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after buying an additional 759,600 shares during the last quarter. Millennium Management LLC increased its holdings in Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after buying an additional 2,299,784 shares during the period. Finally, Capital International Investors raised its position in Catalent by 1.2% during the 4th quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock worth $134,541,000 after buying an additional 34,856 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.